Physician profile
Nusrat Mitu
NPI 1497246276
$485.21
in general payments reported to CMS, 2019-2025
15 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.70 · 2023: $94.51 · 2024: $118 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $74.78 | 2025 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $57.00 | 2025 | |
| Astellas Pharma US INC | $56.52 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $43.87 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $40.49 | 2024 | |
| Janssen Pharmaceuticals, INC | $33.87 | 2024 | Xarelto |
| Millicent US INC | $24.34 | 2025 | Femlyv |
| Novo Nordisk INC | $22.84 | 2023 | Ozempic, Rybelsus |
| Exeltis, USA INC. | $20.73 | 2025 | Slynd |
| Abbvie INC. | $20.33 | 2023 | |
| Exact Sciences Corporation | $19.96 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $19.70 | 2022 | |
| Boston Scientific Corporation | $19.69 | 2024 | Resonate El Icd Vr |
| Amgen INC. | $17.63 | 2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $13.46 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nusrat Mitu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.